A homozygous STIM1 mutation impairs store-operated calcium entry and natural killer cell effector function without clinical immunodeficiency. by Parry, DA et al.
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A homozygous STIM1 mutation
impairs store-operated calcium
entry and natural killer cell
effector function without clinical
immunodeficiency
To the Editor:
Stromal interaction molecule 1 (STIM1) is a transmembrane
protein pivotal to store-operated calcium entry (SOCE) that
localizes to either the cell or endoplasmic reticulum (ER)
membranes, with the N-terminus in either the extracellular space
or the ER, respectively. Plasma membrane ORAI calcium
release–activated calcium modulator 1 (ORAI1) Ca21 channels
are activated by STIM1. Families previously described with
recessive STIM1 mutations (MIM #612783) had life-threatening
viral, bacterial, and fungal infections; developmental myopathy;
hypohidrosis; and amelogenesis imperfecta (AI; generalized
developmental enamel abnormalities).1-3 We investigated a
consanguineous family, segregating a novel syndrome of
recessive AI and hypohidrosis by using autozygosity mapping
and clonal sequencing. A homozygous rare missense mutation
in STIM1 (p.L74P) in the EF-hand domain was identified (see
the Methods and Results sections in this article’s Online Reposi-
tory at www.jacionline.org).
The family was re-evaluated, with particular attention paid to
features associatedwith recessive STIM1mutations (Table I and see
Tables E1-E3 in this article’s Online Repository at www.jacionline.
org). The 2 affected cousins (18 and 11 years old, respectively) did
not have overt clinical immunodeficiency. Further evaluation of
their immune systems showed a normal immunoglobulin profile
with an adequate specific antibody response to both nonlive (pneu-
mococcus, tetanus and, Hib) and live (mumps, measles, and
rubella) vaccinations. In addition, both subjects had detectable
IgG against varicella zoster virus after a previous uncomplicated
primary infection. The younger cousin was also found to have
IgG against EBV viral capsid antigen, suggesting previous expo-
sure, but neither showed any evidence of acute infection or previous
exposure to cytomegalovirus.
Lymphocyte studies showed stable CD8 T-cell depletion in the
older affected subject only. Other lymphocyte subsets, including
CD4 T, natural killer (NK), and B cells, were within the normal
range (Table I). However, despite normal PHA and anti-CD3
simulation responses, T-lymphocyte and NK cell SOCE was
grossly abnormal, which is consistent with disruption of the
Ca21-binding EF-hand and in keeping with previous reports for
recessive STIM1mutations (see Fig E1, A, in this article’s Online
Repository at www.jacionline.org).1-3 The defect in NK cell
SOCE was associated with impaired NK cell effector function,
as shown by assays of granule exocytosis and intracellular
IFN-g production in response to K562 tumor cells (see Fig E1,
B). After recently published mouse studies, which confirmed
the importance of STIM1 to neutrophil SOCE and associated
functions,4we also evaluated neutrophil function. This was found
to be within normal limits.
Despite abnormal immune system SOCE, the affected subjects
in this case appear to be able to compensate for this deficit and
avoid overt immunodeficiency. It is possible that the relative
preservation of T-cell function might compensate for NK cell
dysfunction. Neither might yet have encountered a pathogen
that would expose this particular immune system limitation (see
Table E2). An ability to mount a partial response to viral
infections was reported in a family with clinical immunodefi-
ciency and a history of viral infections caused by a homozygous
missense R429C change affecting the STIM1 cytoplasmic
domain.2 A mouse model characterized by conditional knockout
of Stim1 and Stim2 in both CD41 and CD81 T cells has recently
provided further insight into the importance of Stim1 in immune
system development and virus-specific memory and recall
responses, which prevent acute viral infections from becoming
chronic.5
Recessive STIM1 mutations can be associated with other
immune dysregulations, including autoimmune disease. The
older cousin had a transient episode of idiopathic thrombocyto-
penic purpura when 2 years old that might have been unrelated
to the STIM1mutations. There were no other clinical or serologic
markers consistent with autoimmune disease, and regulatory
T-cell numbers were normal.
Both cousins were intolerant of warm environments and aware
of their inability to sweat normally. This limited the older cousin’s
ability to participate in sport. There was no clinical or serologic
 2015 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy,Asthma& Immunology. This is an open access article under theCCBY license
(http://creativecommons.org/licenses/by/4.0/).
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evidence ofmyopathy. This is in contrast to other recessive STIM1
mutations and also to dominant STIM1 mutations affecting the
EF-hand that cause tubular aggregate myopathy (MIM
#160565).6 Hypomineralized AI affected the primary and
secondary dentitions of both affected cousins (see Fig E2 in this
article’s Online Repository at www.jacionline.org), which is in
keeping with reports of other recessive STIM1 mutations. The
cousins were physically small (height, weight, and head
circumference <0.4th percentile) when assessed at 18 years and
9 years, 10 months of age, respectively. Without comparable
data from other subjects with recessive STIM1 mutations, it is
unclear whether this is a cosegregating feature.
The L74P STIM1 change within the EF-hand domain precedes
the first Ca21-binding aspartate residue by 2 amino acids (see Fig
E2) and therefore might be expected to distort the Ca21-binding
region of the protein. Therefore we compared the response of
mutant YFP-STIM1 (L74P) with the depletion of Ca21 stores
after thapsigargin or cyclopiazonic acid (CPA) treatment with
that of wild-type YFP-STIM1 and the previously published
EF-hand mutant7 YFP-STIM1 (D76A, see Fig E3 in this article’s
Online Repository at www.jacionline.org).
Using total internal reflection fluorescence microscopy
(TIRFM), we replicated previous observations that wild-type
YFP-STIM1 relocalizes to puncta proximal to the plasma
membrane after treatment of transfected HEK293 cells with
2 mmol/L thapsigargin to deplete ER Ca21 stores through
sarcoendoplasmic reticulum calcium transport ATPase
(SERCA) inhibition (see Fig E3, A). The EF-hand mutant
YFP-STIM1 (D76 A) was present in these puncta before thapsi-
gargin treatment, with no observable response to thapsigargin
TABLE I. Summary of the main clinical and clinical immunologic features in subjects with either homozygous or heterozygous STIM1
c.221T>C mutations
Feature V:3 IV:4 IV:3 V:2
STIM1 genotype Homozygous c.221T>C Heterozygous c.221T>C Heterozygous c.221T>C Homozygous c.221T>C
Age at evaluation (y) 18-21 45-48 41 9-12
Persistent infections None None None None
Other infections Infancy: repeated chest
infections but not thereafter
No reported issues No reported issues Infancy: chest, urinary
tract, gastrointestinal
tract, ear, and eye
infections but not
thereafter
Autoimmune disorder Transient ITP aged 2.5 y None Sjogren syndrome None
Lymphocytes
Total (3109/L [1.00-2.80]) 1.50 2.30 2.64 2.34
CD4 (absolute; 3 109/L
[0.300-1.400])
0.841 1.091 1.502 0.908
CD8 (absolute; 3 109/L
[0.200-0.900])
0.055 0.236 0.415 0.488
CD4/CD8 (1.07-1.87) 15.29 4.62 3.62 1.86
NK (absolute; 3 109/L
[0.090-0.600])
0.238 0.581 0.252 0.252
Immunization history Full schedule without adverse
events
Not assessed Not assessed Full schedule without
adverse events
Musculoskeletal Muscle bulk, tone, power, and
reflexes normal; hypermobility
in upper and lower limbs;
CK normal
No issues evident; not
formally examined
No issues evident;
not formally examined
Muscle bulk, tone, power,
and reflexes normal;
hypermobility in upper
and lower limbs;
CK normal
Pupil reaction Normal Normal Normal Normal
Sweating Diminished sweating recognized
from infancy onward; insufficient
sample for sweat test analysis
No reported issues No reported issues Diminished sweating
recognized from infancy
onward; reduced
sweating on starch and
iodine testing
Dental enamel Generalized hypomineralized AI Enamel within normal
limits
Enamel within normal
limits
Generalized hypomineralized AI
Development Global development normal
Height, 156 cm (<0.4th percentile)
Weight, 40.3 kg (<0.4th percentile)
Head circumference, 51.5 cm
(<0.4th percentile)
Not assessed Not assessed Global development normal
Height, 122 cm (0.4th-2nd
percentile)
Weight 24 kg (2nd-9th
percentile)
Head circumference,
50 cm (0.4th percentile)
Further details are presented in Tables E1-E3. Values in boldface are outside the reference ranges.
CK, Creatine kinase; ITP, idiopathic thrombocytopenic purpura.
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(see Fig E3, A). Similarly, mutant YFP-STIM1 (L74P) showed no
response to thapsigargin but also appeared to form constitutive
puncta, which was less distinct in appearance than that for the
D76A mutant (see Fig E3).
We compared Ca21 fluctuations in HEK293 cells transfected
with ORAI-CFP and either wild-type YFP-STIM1, mutant
YFP-STIM1 (D76A), or mutant YFP-STIM1 (L74P; see Fig
E3, B and C). Both YFP-STIM1 (D76A) and YFP-STIM1
(L74P) transfected cells had increased basal Ca21 concentrations
compared with wild-type YFP-STIM1 and reduced peak and
integral responses to CPA-induced SERCA inhibition (see
Fig E3, B and C). However, in contrast to the EF-hand mutant
YFP-STIM1 (D76A), YFP-STIM1 (L74P) did not demonstrate
reduced SOCE after CPAwashout and Ca21 restoration, suggest-
ing that the previously reported desensitization of SOCE observed
with the YFP-STIM1 (D76A) mutant does not occur with the
YFP-STIM1 (L74P) mutant form. Therefore the L74P mutation
appears to result in a distinct molecular phenotype compared
with the loss of function observed in immunodeficient patients
and the constitutive activation observed in patients with
myopathy.
This study is the first to report recessive STIM1mutations in pa-
tients presenting with AI and hypohidrosis without overt clinical
immunodeficiency or myopathy. Clinical immunologic investiga-
tions were consistent with abnormal NK cell and T-lymphocyte
function that might be expected to be associated with ongoing
clinical immunodeficiency. However, despite severely abnormal
SOCE, this was not the case in these patients. Missense mutations
affecting the EF-hand can have very different clinical phenotypes
with respect to the immune system, muscle, sweating, and enamel
formation. This has important implications for clinical evalua-
tion, as well as understanding the biological functions of STIM1.
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Antigen-presenting epithelial cells
can play a pivotal role in airway
allergy
To the Editor:
Professional antigen-presenting cells (APCs; ie, dendritic cells,
macrophages, and B cells) react against exogenous antigens and
initiate an adaptive immune response by presenting antigen
peptides in the groove of the MHC class II molecules. During
inflammation, ectopic expression of MHC class II has been
reported on cells from multiple tissues, including the nasal
mucosa, suggesting an antigen-presenting capacity of epithelial
cells (ECs).1-4 The present investigation was designed to examine
the contribution of nasal epithelial cells (NECs) to the allergic
inflammatory process. The abilities of NECs to take up antigen,
express MHC class II and costimulatory molecules, and stimulate
antigen-specific activation and proliferation of CD41T cells were
investigated by using a human mucosal specimen (see the
Methods section in this article’s Online Repository at www.
jacionline.org).
First, the cell-surface expression of MHC class II and
costimulatory molecules on human and mouse nasal epithelial
cells (MNECs) was confirmed (see Figs E1 and E2 in this article’s
Online Repository at www.jacionline.org). Then the ability of
MNECs to present the antigen ovalbumin (OVA) to naive
T cells was demonstrated. MNECs from sensitized mice
displayed an enhanced MHC class II expression on coculture
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METHODS
Participating family
A consanguineous family of Pakistani heritagewas reviewed in the clinical
genetics clinic with regard to intolerance to warm environments and
generalized dental enamel defects of both dentitions. Sample collection was
performed after obtaining informed consent from the patients according to
the principles of the Declaration of Helsinki and after local ethics
approval. Detailed clinical evaluation was undertaken in appropriate clinical
settings.
Genetic mapping
DNAwas extracted from blood by using standard procedures. DNA from
the 2 affected subjects was genotyped with Affymetrix 6.0 SNP microarrays
(Affymetrix, HighWycombe, United Kingdom), and regions of homozygosity
were identified by using AutoSNPa software.E1 Linkage was confirmed by
means of analysis with fluorescence-labeled polymorphic microsatellite
markers on a genetic analyzer (3130xlGenetic Analyzer; Applied Biosystems,
Warrington, United Kingdom) using genotyping software (GeneMapper
version 4.0; Applied Biosystems). Linkage analyses were performed with
LINKMAP and MLINK from the FASTLINK software package.E2
Clonal and Sanger sequencing
We designed a SureSelect Target Enrichment Reagent (Agilent Techno-
logies, Edinburgh, United Kingdom) targeting coding exonswithin the disease
interval in parallel with the capture of disease intervals for 7 other unrelated
disorders. The affected subject IV:N was sequenced with 80-nt reads on an
Illumina (San Diego, Calif) GAIIx sequencer. Raw data were processed with
the Illumina pipeline (version 1.3.4), and reads were aligned to the human
reference sequence (hg19/GRCh37) by using Novoalign software (Novocraft
Technologies, Selangor, Malaysia). Alignments were processed in the SAM/
BAM formatE3 with Picard and the Genome Analysis Toolkit (GATK)E4,E5 to
correct alignments around indel sites and to mark potential PCR duplicates.
Variants were called in theVariant Call Format by using theUnifiedGenotyper
function of GATK. Filtering of common variation and prediction of functional
consequences of variants were performed by using in-house scripts.
PCR products for STIM1 exon 2 and STK33 exon 3 were amplified and
sequenced by using the primer pairs shown in Table E1. PCR product cleanup
was performed with ExoSAP-IT (Affymetrix) before Sanger sequencing with
theBigDyeTerminatorCycle SequencingKit, version 3.1 (AppliedBiosystems)
and analysis on an ABI 3130XL DNA analyzer (Applied Biosystems).
Flow cytometric analysis of calcium flux
PBMCs were labeled with Dulbecco modified Eagle medium containing
5 mmol/L Indo-1 for 45 minutes at 378C and then washed and cooled on ice.
Cells were incubated for 20 minutes on ice with 5 mg each of unconjugated
CD16 (3G8) and CD3-PerCP (OKT3; BD Biosciences, San Jose, Calif)
antibodies and costained for gating markers CD19 (SJ25C1) and CD56
(NCAM16.2; BD Biosciences). Cells were washed and resuspended in cold
HBSS without calcium. Samples were warmed to 378C and immediately
collected on a UV laser equipped LSRII flow cytometer for 90 seconds and
then spiked during collection with 1:100 goat anti-mouse antibody for a
further 60 seconds (Jackson Laboratory, Bar Harbor, Me), followed by a
1:100 dilution of 200 mmol/L CaCl2 in PBS solution, and collected for a
further 9 minutes. Alternatively, samples were stimulated with the calcium
ionophore ionomycin at 500 ng/mL (Sigma-Aldrich, St Louis, Mo) or
1 mmol/L thapsigargin (Sigma-Aldrich) to deplete ER stores of calcium,
thereby triggering SOCE and an intracellular calcium ([Ca21]i) flux. Analysis
was performedwith FlowJo software (TreeStar, Ashland, Ore), calculating the
ratio of calcium-bound to free Indo-1.
NK cell responses
PBMCs were isolated from diluted blood by means of Ficoll separation,
followed by NK cell purification by means of negative selection (with
immunomagnetic reagents from Miltenyi Biotec, Bergicsch Gladbach, Ger-
many). Isolated NK cells were stimulated with K562 tumor cells alone or in
combination with 20 ng/mL IL-12/IL-18 (PeproTech, Rocky Hill, NJ; to
maximize IFN-g by tumor-stimulated cells) and incubated for 6 hours at 378C
with both GolgiStop and GolgiPlug (BD Biosciences). Cells were stained for
the surface markers CD107a (clone; H4A3), CD56 (NCAM16.2), and CD3
(OKT3; BD Biosciences) before fixation for 15 minutes and permeabilization
for 30 minutes with the AbD Serotec (Oxford, United Kingdom) intracellular
staining kit. Cells were stained with anti–IFN-g (B27) and collected on an
LSR II flow cytometer and analyzed in DIVA software (BD Biosciences).
STIM1 constructs for transfection studies
YFP-STIM1 (Addgene plasmid 18857) and the EF-hand mutant YFP-
STIM1 (D76 A; Addgene plasmid 18859) constructs were provided by Tobias
Meyer through Addgene (Cambridge, Mass). The ORAI1-CFP construct was
provided by Anjana Rao (Addgene plasmid 19757). The L74P mutant YFP-
STIM1 was produced by means of site-directed mutagenesis of the wild-type
YFP-STIM1 plasmid by using the QuikChange II kit (Agilent Technologies,
Santa Clara, Calif) per the manufacturer’s instructions. The sequences of all 4
constructs were confirmed by means of Sanger sequencing, as above.
TIRFM
HEK293 cells (LGC Standards, Middlesex, United Kingdom; ATCC no.
CRL-1573) were grown on glass coverslips coated with poly-D-lysine and
transfected with either wild-type YFP-STIM1, mutant YFP-STIM1 (D76 A),
or mutant YFP-STIM1 (L74P) by using Lipofectamine 2000 (Invitrogen,
Paisley, United Kingdom). Total internal reflection fluorescence (TIRF)
imaging was performed on an inverted microscope (TE-2000E; Nikon)
through a 603 oil-immersion lens (ApoTIRF 603/1.49 numeric aperture;
working distance, 0.12 mm; Nikon, Tokyo, Japan). Cells were maintained at
378C and perfused with standard bath solution; ER store depletion was
induced by 2 mmol/L thapsigargin. The plasma membrane was illuminated by
using TIRFwith a 488-nm argon laser (Prairie Technologies,Middleton,Wis),
which was projected onto the specimen through the lens. Images were
collected on an electron-multiplying CCD camera (DQC-FS, Nikon) by using
NIS Elements imaging software, version 3.2 (Nikon), which was also used for
analysis. Fluorescence intensities were background subtracted after acquisi-
tion and normalized to the initial intensity (F0).
Calcium measurements in overexpressing cells
HEK293 cells were doubly transfected with ORAI1-CFP and either wild-
type YFP-STIM1, mutant YFP-STIM1 (D76A), or mutant YFP-STIM1
(L74P). Twenty-four hours after transfection, cells expressing both CFP and
YFP constructs were selected by using a Becton Dickinson FACSAria II cell
sorter (BD Biosciences) and plated on glass coverslips. In each case basal
[Ca21]i levels were recorded, after which Ca
21 was removed from the
perfusate (replaced with 1 mmol/L ethyleneglycol-bis-(b-aminoethylether)-
N,N,N9,N9-tetra-acetic acid), and new basal levels of [Ca21]i were
determined. Cells were then exposed to CPA (100 mmol/L), and the resultant
transient increases in [Ca21]i levels were measured for peak amplitude and
integral. After washout of CPA, Ca21 (2.5 mmol/L) was readmitted to the
perfusate, and capacitative Ca21 entry was quantified as the maximal increase
in [Ca21]i observed. Data are presented as representative examples (see Fig
E1, B) and mean 6 SEM values (see Fig E1, C) determined from 12 control
recordings, 12 recordings of D76A expressing mutants, and 13 recordings
of L74P expressing mutants. Statistical significancewas determined bymeans
of ANOVA.
RESULTS
Identification of a novel homozygous missense
p.L74P change in STIM1
Autozygosity mapping identified a single region of
homozygosity shared by both affected cousins on chromosome
J ALLERGY CLIN IMMUNOL
VOLUME 137, NUMBER 3
LETTERS TO THE EDITOR 957.e1
11 between rs11606404 and rs3815045 (chr11:2,241,215-
61,669,946, hg19). Multipoint linkage analysis of markers
D11S921, D11S899, D11S915, and D11S4949 against disease
by using LINKMAP results in a maximum LOD score of 3.06
at marker D11S899. On merging of overlapping exon intervals,
the disease interval contained 3,838 RefSeq coding
regions comprising 751,450 bp, 3,784 (739,189 bp or 98.4%) of
which could be targeted while avoiding designing baits over
repeat masked regions. After target enrichment, sequencing,
alignment, and postprocessing, 94.6% of targeted bases were
covered by 5 or more nonduplicate reads with a minimum
Phred-like base quality score of 17 and minimum read mapping
quality of 20.
A total of 526 variants passing standard GATK filters were
identified within 20 bp of a coding exon within the disease locus.
Variants were removed if present in dbSNP129 or in later versions
of dbSNP with a minor allele frequency of 1% or greater, if
present in other samples sequenced locally (n 5 31), or, in the
case of missense variants, if predicted to be benign by using
PolyPhen-2.E6 After these filtering steps, only 3 homozygous
variants remained that might be predicted to alter gene function.
The first of these (NM_152316: c.3G>C)was considered unlikely
to be pathogenic despite altering the initiation codon of ARL14EP
because of the presence of another in-frame initiation codon
immediately adjacent to the mutated codon and lack of
conservation of the first of these ATG codons in mammals. Of
the remaining 2 changes, a missense mutation in STK33
(NM_030906: c.146G>A; p.G49D) was found in 4 of 96 ethni-
cally matched control samples, whereas a missense mutation in
STIM1 (NM_003156: c.221T>C; p.L74P) was excluded in 192
ethnically matched control samples and found to segregate as
expected for a recessively inherited disease within the family.
Subsequent interrogation of the Exome Aggregation Consortium
database showed that although the STK33 variant was present at a
frequency of 1.49% in subjects of South Asian ancestry, the
STIM1 variant was not detected at all in the cohort of 60,706
subjects (Exome Aggregation Consortium, Cambridge, Mass;
http://exac.broadinstitute.org; accessed February 2015).
Accordingly, the homozygous c.221T>C; p.L74P mutation
identified in STIM1 was therefore considered to be the cause of
the observed phenotype based on genetic data and the phenotypic
overlap with previously reported recessive STIM1 and ORAI1
mutations.
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FIG E1. Defective SOCE and impaired NK cell function in STIM1-Leu74Pro patients’ cells. A, Calcium flux
in lymphocytes after anti-CD3/anti-CD16, 1 mmol/L thapsigargin, or 500 nmol/L ionomycin administration.
B, Granule exocytosis and IFN-g production of purified NK cells after stimulation with K562 tumor target
cells alone or with IL-12 and IL-18. Results are representative of 2 experiments performed in duplicate
and corrected for unstimulated control values.
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FIG E2. Hypomineralized AI as the presenting feature in a family with STIM1 L74P change.A, Pedigree of the
consanguineous family investigated. The 2 affected cousins with AI and hypohidrosis are shaded black.
Genotypes of the c.221T>C variant are indicated underneath each family member available for sequencing.
Representative electropherograms are shown alongside the pedigree. B, The hypomineralized AI was
characterized by opaque discolored enamel on clinical examination, with radiographs of unerupted teeth
consistent with a near-normal volume of enamel and a clear difference in radiodensity between enamel
and dentine. *Teeth that have been restored. C, Schematic illustration of STIM1 protein showing the
domain structure. Positions of the AI and hypohidrosis-associated L74P mutation (red), dominant TAM or
Stormorken syndrome mutations (grey), and recessive syndromic immunodeficiency mutations (black)
are indicated above the protein. E-rich, Glutamate-rich region; K, lysine-rich region; MLS, microtubule
tip localization signal; P, proline/serine-rich region; SAM, sterile a-motif domain; SOAR, STIM1 Orai1-
activating region; TM, transmembrane domain. D, Alignment of STIM1 EF-hand orthologous protein
sequences. Although p.L74 is conserved in mammals, it is not as strongly conserved as amino acids
mutated in dominant TAM. E, NMR structure of STIM1.E7 L74 is shown in red, TAM mutations are shown
in dark gray, and Ca21 binding residues, mutation of which cause constitutive STIM1 activation, are shown
in yellow. Substitution of leucine 74 for proline is anticipated to distort the EF-hand loop, interfering with
conformational changes in the presence/absence of Ca21.
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FIG E3. STIM1 localization andCa21flux in cells transfectedwith STIM1 constructs.A, TIRFMofHEK293 cells
transfectedwith eitherwild-type (WT), D76Amutant, or L74Pmutant YFP-STIM1 after treatmentwith 2mmol/
L thapsigargin to deplete ER Ca21 stores. The graph on the bottom left shows changes in TIRF fluorescence
within single puncta areas indicated bywhite circles on the images (ROI1-3). The graph on the bottom right
shows average footprint fluorescence for cells transfected with WT STIM1 (n 5 39), D76 A (n 5 30), or L74P
(n5 31) constructs. B, Representative recordings of cytosolic calcium ([Ca21]i) made in HEK293 cells doubly
transfectedwith ORAI1-CFP and eitherWT (n5 12), D76 A (n5 12), or L74P (n5 13) STIM1-YFP constructs.C,
Bar graphs indicatingmean6 SEM [Ca21]i relating to the presence of extracellular Ca
21 or SERCA inhibition
by CPA. Top row, Mean baseline Ca21 levels in the presence and absence of extracellular Ca21. Bottom row,
Peak responses toCPA, integral of theCPA-evoked response, andpeak valueof capacitative Ca21entry (CCE).
*P < .01 compared with control with control values (ANOVA).
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TABLE E1. Additional clinical features of the 2 subjects with homozygous STIM1 c.221T>C mutations
Feature V3 V2
Birth and neonatal period Full-term (2.3 kg) by using forceps for fetal distress Emergency cesarean section because of fetal decelerations
at 36/40 wk
Birth weight, 1.94 kg (<3rd percentile)
Apgar score, 9 at 1 and 5 minutes, respectively
Special care baby unit for 1 mo, establishing feeds with
nasogastric tube feeds for the first 2 wk
During this time, there was 1 episode of unexplained fever.
Unexplained neonatal hypercalcemia settled spontaneously.
Nails and hair Normal Normal
Dysmorphic features None None
Other medical history Asthma diagnosed in infancy
Evaluated in infancy for cystic fibrosis (negative) after
repeated chest infections
At age 17 y, had a spontaneous pneumothorax of the left
lung requiring pleurodesis
Four apical bullae were found on imaging.
Five months later, he had a right pneumothorax
secondary to an apical bulla also requiring pleurodesis.
At aged 18 y, V3 was evaluated with regard to macular
pigmentation and bilateral drusen on both maculae,
and mild congenital lens opacities were identified.
Asthma diagnosed in infancy
Eczema
Generalized problems with increased leg fatigability and
clumsiness
Tight Achilles tendons of unknown cause
Bilateral pes cavus
Hypermobility in upper limbs
Allergies Allergic to red food coloring None
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TABLE E2. Summary of clinical immunologic data in subjects with either homozygous or heterozygous STIM1 c.221T>C mutations
Feature
VI:2 V:1 V:2 VI:3
Homozygous
c.221T>C
Heterozygous
c.221T>C
Heterozygous
c.221T>C
Homozygous
c.221T>C
Year of evaluation 2011 2014 2011 2014 2011 2012 2013
Bacterial antibodies
Pneumococcal (mg/mL) 209.0 2 101.0 2 82.2 181.0 2
Tetanus (IU/mL) 0.890 2 5.320 2 0.960 0.620 2
Haemophilus species (mg/mL) 0.230 2 0.240 2 <0.110 0.430 2
Viral antibodies
HSV IgG ND ND 2 1ve 2 2 2
VZV IgG 1ve 1ve 2 1ve 2 1ve 2
CMV IgM ND 2 2 ND 2 2 2
CMV IgG ND ND 2 1ve 2 ND 2
EBV VCA IgM ND 2 2 ND 2 2 2
EBV VCA IgG ND 2 2 1ve 2 1ve 2
Measles IgG 2 1ve 2 1ve 2 2 2
Mumps IgG 2 1ve 2 1ve 2 1ve 2
Rubella IgG 2 1ve 2 1ve 2 1ve 2
Viral PCR
EBV 2 ND 2 2 2 2 2
CMV 2 ND 2 2 2 2 2
Adenovirus 2 ND 2 2 2 2 2
Lymphocytes
Total (3109/L [1.00-2.80]) 1.50 1.32 2.30 2.35 2.64 2.34 2.20
CD4/CD8 (1.07-1.87) 15.29* 10.58 4.62 5.87 3.62 1.86 1.9
CD3 (absolute; 3 109/L [0.700-2.100]) 0.921 0.949 1.365 1.605 1.968 1.504 1.457
CD8 (absolute; 3 109/L [0.200-0.900]) 0.055 0.080 0.236 0.231 0.415 0.488 0.489
NK (absolute; 3 109/L [0.090-0.600]) 0.238 0.191 0.581 0.449 0.252 0.252 0.152
CD4 (absolute; 3 109/L [0.300-1.400]) 0.841 0.846 1.091 1.355 1.502 0.908 0.929
CD19 (absolute;3 109/L [0.100-0.500]) 0.258 0.127 0.245 0.282 0.381 0.574 0.564
CD31 cells (%) 71 75 64 68 75 64 66
CD41 cells (%) 66 66 51 57 57 39 41
CD81 cells (%) 4 6 11 10 16 21 21
CD561CD161 cells (%) 14 14 24 19 10 11 7
CD191 cells (%) 15 9 10 12 14 24 26
CD41FOXP31 cells Normal Normal 2 2 2 2 2
T-cell proliferation after stimulation
PHA Normal Normal 2 Normal 2 Normal 2
Anti-CD3 antibody Normal Normal 2 Normal 2 Normal 2
Immunoglobulins
IgG (g/dL [6.0-16.0]) 11.8 2 11.8 2 12.4 9.6 2
IgG1 (g/L [3.62-10.27]) 7.48 2 2 2 2 2 2
IgG2 (g/L [0.81-4.72]) 2.66 2 2 2 2 2 2
IgG3 (g/L [0.138-1.058]) 0.420 2 2 2 2 2 2
IgG4 (g/L [0.049-1.085]) 0.224 2 2 2 2 2 2
IgA (g/dL [0.80-4.00]) 1.85 2 2.53 2 3.51 3.95 2
IgM (g/dL [0.25-2.00]) 2.08 2 0.77 2 1.20 1.12 2
IgE (kU/L [0.5-120.0]) <2.0 2 195.0 2 24.4 157.0 2
Other antibodies
ANA 2ve 2ve 2ve 2ve 1ve 1ve 2
dsDNA (IU/mL [0-50]) 2 2ve 2 2 2ve 2ve 2
Rheumatoid factor (IU/mL [<20]) <15 <15 <15 2 122 2 2
Complement
C3 (g/dL [0.75-1.65]) 1.14 2 1.02 2 1.34 2 2
C4 (g/dL [0.12-0.40]) 0.28 2 0.31 2 0.44 2 2
2, Not investigated; ANA, antinuclear antibody; CMV, cytomegalovirus; dsDNA, double-strand DNA; ND, not detected; RNP, ribonucleoprotein; VCA, viral capsid antigen; 1ve,
positive; 2ve, negative; VZV, varicella zoster virus. Values in boldface are outside the reference ranges.
*On resampling 3 months later: CD4/CD8 ratio, 14.36; CD8, 0.092.
Positive (homogenous: weak RNP antibody positive).
Positive (nucleolar).
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TABLE E3. Summary of key clinical findings associated with individual reported recessive STIM1mutations and summarized key clinical findings associated with dominant STIM1
mutations
Feature Recessive homozygous mutations Dominant mutations
Reference Picard et al, 2009E8 Byun et al,
2010E9
Fuchs et al, 2012E10 Wang et al 2014E11 Schaballie et al,
2015E12
This study Bohm et al, 2013E13 Morin et al,
2014E14
Individual (AR) or
diagnosis (AD)
Pr1, Pr2, and Pr3* Pr4 Pr5 and Pr6 Pr7 Pr8 and Pr9 V2 and V3 Tubular aggregate
myopathy
Stormorken
syndrome
Predicted protein
effect of mutation
No protein No protein p.429 R>C p. 146A>V p.165P>Q p.74 L>P All missense in the
EF-hand
p.304 R>W
Age at last
examination (y)
1, 5, 6, and 9 2 1.7 and 6 6 8 and 21 11 and 21 Various Various
Immune deficiency Life-threatening
infections
Life-threatening
infections
Life-threatening
infections
History of frequent
throat infections:
no immunologic
evaluation performed
Life-threatening
infections
No persistent
severe infection
NR NR
Other immune
dysregulation
AIHA
ITP
AIHA AIHA
ITP
NR Colitis, psoriasis V3 transient ITP NR NR
Skeletal muscle Developmental
skeletal myopathy
with hypotonia,
profound
NR Developmental
skeletal myopathy
with hypotonia, mild
NR Developmental
skeletal myopathy,
profound
No abnormalities Clinical myopathy
except with 1 mutation
Increased CK typical
Clinical myopathy
Increased CK
Mydriasis Yes NR Yes NR No No NC Yes
Sweat glands NC NR Anhidrosis NR Anhidrosis Hypohidrosis NC NC
Dental enamel Abnormal NR Abnormal Abnormal Abnormal Abnormal NC NC
Died Pr1 died 9 y (during
HSCT)
Pr2 died 1.5 y
(encephalitis)
Pr4 died 2 y
(Kaposi
sarcoma)
Pr6 died 1.7 y (sepsis) NR NA NA NA NA
Alive Pr3 alive at 6 y
(HSCT at 1.3 y)
NA Pr5 alive (HSCT) Pr7 lost to follow-up
at 5 y
Pr8 and Pr9 alive V2 and V3 alive All alive All alive
AIHA, Autoimmune hemolytic anemia; AD, autosomal dominant; AR, autosomal recessive; CK, creatine kinase; HSCT, hematopoietic stem cell transplantation; ITP, idiopathic thrombocytopenic purpura; NA, not applicable; NC, no
comment made; NR, comment made but feature not recognized.
*Mutation confirmed in Pr1 and Pr3; no DNA sample available for Pr2.
Mutation identified after death.
A missense change reported in tubular aggregate myopathy and the missense change reported as the cause of Stormorken syndrome have also been identified as the causes of York platelet syndrome, which is characterized by myopathy
and platelet abnormalities (Markello et al, 2015E15).
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